BELLUS Health Inc. – NASDAQ:BLU
BELLUS Health stock price today
$14.74
+0.01
+0.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in less than a minute
BELLUS Health stock price monthly change
+2.08%
month
BELLUS Health stock price quarterly change
+93.43%
quarter
BELLUS Health stock price yearly change
+82.86%
year
BELLUS Health key metrics
Market Cap | 1.86B |
Enterprise value | 774.26M |
P/E | -10.07 |
EV/Sales | 48391.45 |
EV/EBITDA | -10.72 |
Price/Sales | 52907.57 |
Price/Book | 2.08 |
PEG ratio | 0.08 |
EPS | -0.52 |
Revenue | 3.17B |
EBITDA | -135.56M |
Income | -108.19M |
Revenue Q/Q | 41278850.95% |
Revenue Y/Y | 19833329.33% |
Profit margin | -453737.5% |
Oper. margin | -454418.75% |
Gross margin | 0% |
EBIT margin | -454418.75% |
EBITDA margin | -4.27% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBELLUS Health stock price history
BELLUS Health stock forecast
BELLUS Health financial statements
| Dec 2022 | 4K | -18.24M | -456150% |
|---|---|---|---|
| Mar 2023 | 3K | -25.06M | -835333.33% |
| Jun 2023 | 1.52B | -22.18M | -1.46% |
| Sep 2023 | 1.65B | -42.69M | -2.59% |
| 2023-08-09 | 0.24 | -0.18 |
|---|
| Dec 2022 | 407820000 | 16.80M | 4.12% |
|---|---|---|---|
| Mar 2023 | 379543000 | 10.63M | 2.8% |
| Jun 2023 | 3116985036 | 1.95B | 62.62% |
| Sep 2023 | 3094172588 | 1.91B | 61.74% |
| Dec 2022 | -30.73M | 45.01M | -480K |
|---|---|---|---|
| Mar 2023 | -27.10M | 25.27M | -219K |
| Jun 2023 | -28.08M | 26.53M | -267.64M |
| Sep 2023 | -17.68M | -14.98M | 1.91M |
BELLUS Health alternative data
| Aug 2023 | 74 |
|---|---|
| Sep 2023 | 74 |
| Oct 2023 | 74 |
| Nov 2023 | 74 |
| Dec 2023 | 74 |
| Jan 2024 | 74 |
| Feb 2024 | 74 |
| Mar 2024 | 74 |
| Apr 2024 | 74 |
| May 2024 | 74 |
| Jun 2024 | 74 |
| Jul 2024 | 74 |
BELLUS Health other data
23.89%
-76.11%
of BLU is owned by hedge funds
49
-70
27.55M
-86.15M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 26 Apr 2021 Issue date: 16 Dec 2021 |
Grant Utility: Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid Filling date: 24 Apr 2020 Issue date: 1 Jun 2021 |
Grant Utility: Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid Filling date: 15 Feb 2019 Issue date: 8 Dec 2020 |
Application Filling date: 24 Apr 2020 Issue date: 13 Aug 2020 |
Application Filling date: 15 Feb 2019 Issue date: 9 Jan 2020 |
| Insider | Compensation |
|---|---|
Dr. Catherine M. Bonuccelli (1958) Chief Medical Officer | $444,280 |
Mr. Roberto Francesco Bellini (1980) Pres, Chief Executive Officer & Director | $424,990 |
Mr. Ramzi Benamar (1973) Chief Financial Officer | $327,930 |
Dr. Denis Garceau (1957) Chief Scientific Officer | $267,310 |
Mr. Francois Desjardins C.A., CPA, CPA, CA (1963) Senior Vice President of Fin. | $173,510 |
-
What's the price of BELLUS Health stock today?
One share of BELLUS Health stock can currently be purchased for approximately $14.74.
-
When is BELLUS Health's next earnings date?
Unfortunately, BELLUS Health's (BLU) next earnings date is currently unknown.
-
Does BELLUS Health pay dividends?
No, BELLUS Health does not pay dividends.
-
How much money does BELLUS Health make?
BELLUS Health has a market capitalization of 1.86B. BELLUS Health made a loss 76.08M US dollars in net income (profit) last year or -$0.18 on an earnings per share basis.
-
What is BELLUS Health's stock symbol?
BELLUS Health Inc. is traded on the NASDAQ under the ticker symbol "BLU".
-
What is BELLUS Health's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BELLUS Health?
Shares of BELLUS Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BELLUS Health's key executives?
BELLUS Health's management team includes the following people:
- Dr. Catherine M. Bonuccelli Chief Medical Officer(age: 67, pay: $444,280)
- Mr. Roberto Francesco Bellini Pres, Chief Executive Officer & Director(age: 45, pay: $424,990)
- Mr. Ramzi Benamar Chief Financial Officer(age: 52, pay: $327,930)
- Dr. Denis Garceau Chief Scientific Officer(age: 68, pay: $267,310)
- Mr. Francois Desjardins C.A., CPA, CPA, CA Senior Vice President of Fin.(age: 62, pay: $173,510)
-
How many employees does BELLUS Health have?
As Jul 2024, BELLUS Health employs 74 workers.
-
When BELLUS Health went public?
BELLUS Health Inc. is publicly traded company for more then 24 years since IPO on 27 Oct 2000.
-
What is BELLUS Health's official website?
The official website for BELLUS Health is bellushealth.com.
-
Where are BELLUS Health's headquarters?
BELLUS Health is headquartered at 275 Armand-Frappier Boulevard, Laval, QC.
-
How can i contact BELLUS Health?
BELLUS Health's mailing address is 275 Armand-Frappier Boulevard, Laval, QC and company can be reached via phone at +1 450 680 4500.
BELLUS Health company profile:
BELLUS Health Inc.
bellushealth.comExchange:
NASDAQ
Full time employees:
74
Industry:
Biotechnology
Sector:
Healthcare
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Laval, QC H7V 4A7
CIK: 0001259942
ISIN: CA07987C2040
CUSIP: 07987C204
